BioPharma Resources

Drug Trial Radar · NCT03013218

A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)

A Phase 1, Dose Escalation Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)

Last checked: Nov 19, 2026Latest source record: Aug 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

174

Actual

Start

Feb 3, 2017

Primary completion

Feb 1, 2022

Study completion Jul 8, 2025

Sponsor

Lead sponsor
ALX Oncology Inc.Industry
Sponsor type
Industry
First posted
Jan 6, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase 1, dose escalation study of evorpacept (ALX148) in patients with advanced solid tumors and lymphoma

Conditions

  • Metastatic Cancer
  • Solid Tumor
  • Advanced Cancer
  • NonHodgkin Lymphoma

Interventions

  • Evorpacept (ALX148)Drug

    Evorpacept (ALX148)

  • PembrolizumabDrug

    Keytruda

  • TrastuzumabDrug

    Herceptin

  • RituximabDrug

    Rituxan

  • Ramucirumab + PaclitaxelDrug

    Standard of care chemotherapy

  • 5-FU + CisplatinDrug

    Standard of care chemotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicities (Number of participants with a DLT)Time frame: Up to 28 days

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Colorado Denver

    Denver, Colorado

  • Yale University

    New Haven, Connecticut

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • START-Midwest

    Grand Rapids, Michigan

  • Seattle Cancer Care Alliance

    Seattle, Washington

  • Seoul National University Bundang Hospital

    Seongnam, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital, Yonsei University

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.